Jaringan Laboratorium Medis

Vol. 6 No. 1 (2024): May 2024
Original Articles

Differences in Vitamin D3 Levels in Pulmonary Tuberculosis Patients Before and After One Month of Anti-Tuberculosis Drug Therapy

PDF
  • Rachmad Bayu Kuncara,
  • Dewina Zumrotin Najiah

Published 2024-05-31

Keywords

  • Pulmonary tuberculosis,
  • Anti-Tuberculosis Drugs,
  • Vitamin

Copyright (c) 2024 Jaringan Laboratorium Medis

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite

Differences in Vitamin D3 Levels in Pulmonary Tuberculosis Patients Before and After One Month of Anti-Tuberculosis Drug Therapy. (2024). Jaringan Laboratorium Medis, 6(1), 18-25. https://doi.org/10.31983/jlm.v6i1.11379

CrossMark



Dimensions

If it doesn't Appear, click here



PlumX Metrics



Impact Factor

or, Visit on here

Abstract

Pulmonary tuberculosis is an infectious disease caused by infection with the bacteria Mycobacterium tuberculosis. Patients diagnosed with pulmonary tuberculosis will receive Anti-Tuberculosis Drug (OAT) therapy for six months. In the first two months or what is called the intensive phase, the patient will be given a combination of OAT in the form of rifampicin, isoniazid, ethambutol and pyrazinamide. Several types of anti-tuberculosis drugs have the potential to affect vitamin D3 metabolism, either by interfering with absorption, metabolism or changing the action of vitamin D3. The long-term treatment process for pulmonary tuberculosis also results in a decrease in vitamin D3 levels in the blood. This study aims to determine the difference in vitamin D3 levels in pulmonary tuberculosis sufferers before and after one month of anti-tuberculosis drug therapy. This type of research is descriptive observational with a prospective cohort design without comparison. The total sample was 16 newly diagnosed pulmonary tuberculosis sufferers at the Bangetayu, Kedungmundu and Tlogosari Wetan Health Centers, Semarang City. Vitamin D3 levels in serum samples were examined using the ELISA method. The mean vitamin D3 level before OAT therapy was 19.00 ± 10.45 ng/mL, the level decreased after OAT therapy, namely 18.51 ± 4.74 ng/mL. These results indicate that administration of anti-tuberculosis drugs may have an effect on vitamin levels.

PDF

Downloads

Download data is not yet available.

References

  1. Brighenti, S., Bergman, P., & Martineau, A. R. (2018). Vitamin D and Tuberculosis: where next? Journal of Internal Medicine, 284(2), 145–162. https://doi.org/10.1111/JOIM.12777
  2. Bruns, H., & Stenger, S. (2014). New Insights Into the Interaction of Mycobacterium Tuberculosis and Human Macrophages. Future microbiology, 9(3), 327–341. https://doi.org/10.2217/FMB.13.164
  3. Chesdachai, S., dkk. (2016). The Effects of First-Line Anti-Tuberculosis Drugs on the Actions of Vitamin D in Human Macrophages. Journal of Clinical & Translational Endocrinology, 6, 23–29. https://doi.org/10.1016/J.JCTE.2016.08.005
  4. Dinas Kesehatan Kota Semarang. (2021). Profil Kesehatan Kota semarang 2021. www.dinkes.semarangkota.go.id
  5. Dinas Kesehatan Provinsi Jateng. (2021). Profil Kesehatan Jateng 2021.
  6. Dini, C., & Bianchi, A. (2012). The potential role of vitamin D for prevention and treatment of tuberculosis and infectious diseases. Annali dell’Istituto superiore di sanita, 48(3), 319–327. https://doi.org/10.4415/ANN_12_03_13
  7. Habibzadeh, S., dkk. (2013). Serum Parathormone Levels as a Sign for Vitamin D Deficiency During Anti-Tuberculosis Therapy, a Pilot Study. Archives of Clinical Infectious Diseases 2013 8:3, 8(3), 18271. https://doi.org/10.5812/ARCHCID.18271
  8. Harahap, F. H. (2022). The Association Between Tuberculosis Risk Factors and Vitamin D Serum Level on Tuberculosis Patients. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 9(3), 1–8. https://doi.org/10.53366/jimki.v9i3.415
  9. Huang, S. J., dkk. (2017). Vitamin D deficiency and the risk of tuberculosis: a meta-analysis. Drug Design, Development and Therapy, 11, 91–102. https://doi.org/10.2147/DDDT.S79870
  10. Jaimni, V., dkk. (2021). Association of Vitamin D Deficiency and Newly Diagnosed Pulmonary Tuberculosis. Pulmonary Medicine, 2021. https://doi.org/10.1155/2021/5285841
  11. Kartikasari, W., dkk. (2021). The Correlation Between Acid Fast Bacilli of the Intensive and Continuation Phase in Pulmonary Tuberculosis Patients’ Category 1. Jurnal Farmasi Sains dan Praktis, 7(1), 2579–4558. http://journal.ummgl.ac.id/index.php/pharmacy
  12. Kemenkes RI. (2021). PROFIL KESEHATAN INDONESIA 2021.
  13. Kuncara, R. B., dkk. (2022). The Effect of Various Sun Time Under Exposure to Ultraviolet Light of the Sun on Interleukin 10 Cytokine. Jurnal Biosains Pascasarjana, 24(1), 29–33. https://doi.org/10.20473/JBP.V24I1.2022.29-33
  14. Naik, A. L., dkk. (2017). Effect of DOTS Treatment on Vitamin D Levels in Pulmonary Tuberculosis. Journal of Clinical and Diagnostic Research : JCDR, 11(4), BC18. https://doi.org/10.7860/JCDR/2017/24501.9759
  15. Nonglait, P., dkk. (2017). Biochemical abnormalities and Vitamin D levels in sputum positive pulmonary tuberculosis. International Journal of Biomedical and Advance Research, 8(06), 255–258. https://doi.org/doi.org/10.7349/ijbar
  16. Nouri-Vaskeh, M., dkk. (2019). Vitamin D Deficiency among Patients with Tuberculosis: a Cross-Sectional Study in Iranian-Azari Population. Tanaffos, 18(1), 11–17.
  17. Pebriyani, U., & Kurniati, M. (2021). Tuberculosis. Gracias Logis Kreatif.
  18. Ramdan, A., Dias Ismiarto, Y., Yulianto, F. K., & Albana, R. (2018). Kadar Vitamin D [25(OH)D] Serum Pasien Tuberkulosis Tulang Belakang dan Tuberkulosis Paru di Bandung, Indonesia: Studi Epidemiologi (Vol. 45, Nomor 6).
  19. Rimahardika, R., Subagio, H. W., & Wijayanti, H. S. (2017). Asupan Vitamin D dan Paparan Sinar Matahari Pada Orang yang Bekerja di Dalam Ruangan dan di Luar Ruangan. Journal of Nutrition College, 6(4), 333–342. https://doi.org/10.14710/JNC.V6I4.18785
  20. Siswanto, dkk. (2012). Vitamin D as Supportive Treatment Improve The Sputum Conversion and Radiographic Finding in Tuberculosis Patients. Jurnal Kedokteran Brawijaya, XXV(3), 128–132.
  21. Somantri, I. (2007). Asuhan Keperawatan pada Pasien dengan Gangguan Sistem Pernapasan. Salemba Medika.
  22. Sugiarti, S., Ricky, M., Ramadhian, M. R., & Carolia, N. (2018). Vitamin D sebagai Suplemen dalam Terapi Tuberkulosis Paru. Jurnal Majority, 7(2), 198–202. https://juke.kedokteran.unila.ac.id/index.php/majority/article/view/1876
  23. Talat, N., dkk. (2010). Vitamin D deficiency and tuberculosis progression. Emerging Infectious Diseases, 16(5), 853–855. https://doi.org/10.3201/eid1605.091693
  24. Tostmann, A., dkk. (2010). Serum 25-hydroxy-vitamin D3 concentrations increase during tuberculosis treatment in Tanzania. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 14(9), 1147–1152.
  25. WHO. (2021). GLOBAL TUBERCULOSIS REPORT 2021. http://apps.who.int/bookorders.
  26. Wu, S., & Sun, J. (2012). Vitamin D, Vitamin D Receptor, and Macroautophagy in Inflammation and Infection. NIH Public Access, 11(59), 325–335. http://www.vitamindcouncil.org
  27. Yaqoob, H. A., dkk. (2021). Vitamin D deficiency and Tuberculosis in Basrah: The Effect of Anti-tuberculosis Drugs. The Medical Journal of Basrah University, 39(1), 61–72. https://doi.org/10.33762/MJBU.2021.128899.1047